Kristen Goliak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kristen Goliak has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Allison Schriever
University of Illinois Chicago Retzky College of Pharmacy Chicago Illinois USA
1 shared publication- Benjamin Shultz
University of Illinois Chicago Retzky College of Pharmacy Chicago Illinois USA
1 shared publication - Jeffrey Mucksavage
Retzky College of Pharmacy University of Illinois Chicago Chicago Illinois USA
1 shared publication - Kathryn Sawyer
University of Illinois Chicago
1 shared publication Kay Yamamoto
University of Illinois Chicago Retzky College of Pharmacy Chicago Illinois USA
1 shared publication- Mathew Thambi
University of Illinois Chicago Retzky College of Pharmacy Chicago Illinois USA
1 shared publication
Latest Publications
- 9 July 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (8) , e70260
Identifying Foundational Drug Knowledge in Pharmacy Education Using a Structured Consensus Framework
Background: Foundational drug knowledge is a central expectation for pharmacy practice‐readiness, yet programs lack consensus‐based guidance on which medications to prioritize or how intensively to assess them. Programs often use volume‐derived drug lists as a pragmatic starting point, but such lists may not fully reflect the breadth of medications encountered across diverse practice settings. The purpose of the study is to identify a consensus‐based foundational drug list reflective of the breadth of pharmacy practice. Methods: A multi‐phase consensus study was conducted using the Lawshe method to establish content validity of essential drugs for a pharmacy curriculum. An initial inventory of 1381 drugs taught across an integrated therapeutics curriculum was reviewed by a nine‐member academic expert panel, followed by evaluation of the refined list by 10 practicing pharmacists representing diverse clinical settings. Responses were merged to form a 19‐member consensus panel. Drugs meeting statistical thresholds for essentiality were grouped by strength of expert agreement. The resulting list was compared with a commercially available Top 300 Drugs list using the Jaccard Similarity index. Results: A total of 218 drugs achieved consensus inclusion: 78 reached unanimous consensus with a content validity ratio (CVR) = 1.0, 83 reached near‐complete consensus (CVR = 0.895), and 57 met the minimum consensus threshold (CVR = 0.789). Cardiovascular and hematology, central nervous system, and anti‐infective classes were most heavily represented among drugs with the strongest consensus. Comparison with the commercial list yielded a Jaccard Similarity index of 0.408 and an overlap coefficient of 0.697. Concordance with the commercial list declined as consensus strength decreased, from 85% among unanimously endorsed drugs to 65% at near‐complete consensus and 56% at the minimum threshold, with systematic gaps in opioid analgesics, intravenous antibiotics, and emergency and critical care medications. Conclusion: This study provides a validated, consensus‐derived framework of 218 foundational drugs and a replicable methodology that programs may use or adapt. The primary curricular application operates through focused, longitudinal assessment rather than changes to taught content.
- 9 July 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (8) , e70260
Identifying Foundational Drug Knowledge in Pharmacy Education Using a Structured Consensus Framework
Background: Foundational drug knowledge is a central expectation for pharmacy practice‐readiness, yet programs lack consensus‐based guidance on which medications to prioritize or how intensively to assess them. Programs often use volume‐derived drug lists as a pragmatic starting point, but such lists may not fully reflect the breadth of medications encountered across diverse practice settings. The purpose of the study is to identify a consensus‐based foundational drug list reflective of the breadth of pharmacy practice. Methods: A multi‐phase consensus study was conducted using the Lawshe method to establish content validity of essential drugs for a pharmacy curriculum. An initial inventory of 1381 drugs taught across an integrated therapeutics curriculum was reviewed by a nine‐member academic expert panel, followed by evaluation of the refined list by 10 practicing pharmacists representing diverse clinical settings. Responses were merged to form a 19‐member consensus panel. Drugs meeting statistical thresholds for essentiality were grouped by strength of expert agreement. The resulting list was compared with a commercially available Top 300 Drugs list using the Jaccard Similarity index. Results: A total of 218 drugs achieved consensus inclusion: 78 reached unanimous consensus with a content validity ratio (CVR) = 1.0, 83 reached near‐complete consensus (CVR = 0.895), and 57 met the minimum consensus threshold (CVR = 0.789). Cardiovascular and hematology, central nervous system, and anti‐infective classes were most heavily represented among drugs with the strongest consensus. Comparison with the commercial list yielded a Jaccard Similarity index of 0.408 and an overlap coefficient of 0.697. Concordance with the commercial list declined as consensus strength decreased, from 85% among unanimously endorsed drugs to 65% at near‐complete consensus and 56% at the minimum threshold, with systematic gaps in opioid analgesics, intravenous antibiotics, and emergency and critical care medications. Conclusion: This study provides a validated, consensus‐derived framework of 218 foundational drugs and a replicable methodology that programs may use or adapt. The primary curricular application operates through focused, longitudinal assessment rather than changes to taught content.